Br J Cancer: Apalutamide: Potential Sensitizer for Radiotherapy of Prostate Cancer

Prostate cancer is the most common tumor in men.
Radical prostatectomy and radiotherapy have a high cure rate for early stage patients
.

Prostate cancer is the most common tumor in men.
Radical prostatectomy and radiotherapy have a high cure rate for early stage patients
.

Prostate cancer is the most common tumor in men.

Radiotherapy is a treatment method widely used in high-risk local cancer patients
.

When the disease progresses to the locally advanced stage, radical radiotherapy combined with androgen (AR) deprivation of luteinizing hormone releasing hormone analogs and bicalutamide (bicalutamide) treatment strategy is the best choice for the disease

Apalutamide is a non-steroidal androgen receptor inhibitory drug, which can selectively bind to AR, and has an affinity 7-10 times higher than that of Kalutamide.

It can effectively prevent the nuclear transport of AR and its The ability to activate genes that promote tumor progression

Previous studies have shown that bicalutamide may exhibit androgen agonism in hormone-dependent prostate cancer cells
.

Unlike bicalutamide, apalutamide does not show a switch from antagonist to agonist

In 2018, the US Food and Drug Administration has approved for the treatment of asymptomatic amine A Palu non-metastatic castration-resistant prostate cancer
.

manage

In vitro experiments verify that apalutamide increases PCa cells' sensitivity to radiotherapy

In vitro experiments verify that apalutamide increases PCa cells' sensitivity to radiotherapy

This study aims to compare the effects of bicalutamide and apalutamide on the sensitivity of prostate cancer cells to radiotherapy
.

Explore whether a new generation of anti-androgen drug Apalutamide can improve the efficacy of radiotherapy in patients

This study aims to compare the effects of bicalutamide and apalutamide on the sensitivity of prostate cancer cells to radiotherapy

In vivo experiments verify that apalutamide makes PCa cells sensitized to radiotherapy

In vivo experiments verify that apalutamide makes PCa cells sensitized to radiotherapy

The results of radiotherapy dose response and clone formation test showed that apalutamide has stronger radiosensitizing activity on all three cell lines
.

Confocal imaging showed that apalutamide and bicalutamide have similar DNA double-strand break repair kinetics

There is no difference between the two on the effect of apoptosis
.

When apalutamide was combined with radiotherapy, only G1/S cells were found to have cell death phenotypes including nuclear rupture and cell pyknosis
.
Further studies have shown that in SCID and R2G2 mouse xenograft models, the efficacy of apalutamide combined with radiotherapy is significantly improved and can cause extensive necrosis of xenografts
.

In SCID and R2G2 mouse xenograft models, the efficacy of apalutamide combined with radiotherapy is significantly improved, and can cause extensive necrosis of xenografts
.
In SCID and R2G2 mouse xenograft models, the efficacy of apalutamide combined with radiotherapy is significantly improved, and can cause extensive necrosis of xenografts
.

All in all, the results of the study revealed that apalutamide combined with radiotherapy is more effective than bicalutamide in the treatment of prostate cancer
.
Therefore, the researchers recommend that further clinical studies be conducted to analyze whether apalutamide can improve the cure rate of patients
.

Apalutamide combined with radiotherapy is more effective than bicalutamide in the treatment of prostate cancer
.
Therefore, the researchers recommend that further clinical studies be conducted to analyze whether apalutamide can improve the cure rate of patients
.
Apalutamide combined with radiotherapy is more effective than bicalutamide in the treatment of prostate cancer
.
Therefore, the researchers recommend that further clinical studies be conducted to analyze whether apalutamide can improve the cure rate of patients
.

Original source:

Kakouratos, C.
, Kalamida, D.
, Lamprou, I.
et al.
Apalutamide radio-sensitisation of prostate cancer.
Br J Cancer (01 September 2021).

Apalutamide radio-sensitisation of prostate cancer.

 

Leave a message here